Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY24 results · Apr–Jun 2023
Sun Pharma Advanced Research Company reported revenue from operations of ₹23.95 crore (down 15.8% from Q1 FY23) and net loss of ₹95.35 crore for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 23.95 | 28.46 | −15.8% | 47.69 | −49.8% |
| Other income | 10.19 | 0.18 | 57x | 10.73 | −5.0% |
| Total income | 34.14 | 28.64 | +19.2% | 58.42 | −41.6% |
| Profit before tax | (95.35) | (82.35) | Loss widened | (81.99) | Loss widened |
| Net profit for the period | (95.35) | (82.35) | Loss widened | (81.99) | Loss widened |
| EPS, basic (₹) | (2.94) | (3.03) | not comparable | (2.55) | Loss widened |
| Net margin (%) | -398.1 | -289.4 | -171.9 |
Standalone
- Filed with BSE
- 07 Aug 2023, 17:31 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE